Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1481 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Abbott releases Compare trial results

Compare trial endpoint was major adverse cardiac events (MACE) at two years, which is a composite of all death, non-fatal heart attack (myocardial infarction or MI) and target

Arrowhead raises ownership in Calando Pharma

The exchange follows recent milestones achieved by Calando, including several notable first accomplishments in RNAi technology that include proof of the first definitive systemic siRNA delivery and first

Dynavax initiates N8295 Phase 1b trial

Dynavax Phase 1b study is expected to evaluate the safety of the combination of N8295 and Novartis’ investigational H5N1 avian influenza vaccine. N8295 is a fusion protein comprised